Eli Lilly's (LLY) Oral GLP-1, Orforglipron, delivered superior blood sugar control and weight loss compared to oral Semaglutide in head-to-head Type 2 Diabetes trial, published in the Lancet

Eli Lilly's (LLY) Oral GLP-1, Orforglipron, delivered superior blood sugar control and weight loss compared to oral Semaglutide in head-to-head Type 2 Diabetes trial, published in the Lancet.

Eli Lilly's new oral GLP-1 drug, Orforglipron, has shown superior results in blood sugar control and weight loss compared to Semaglutide in a recent Type 2 Diabetes trial. This could position Eli Lilly favorably in the competitive diabetes treatment market, potentially enhancing their revenue outlook and impacting peer companies in the pharmaceuticals sector.